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Abstract No data is so far available on the relation
between glucose values and insulin resistance and mortal-
ity, both at short- and long-term, in patients with acute
heart failure syndromes (AHF). We prospectively assessed
in 100 consecutive non-diabetic AHF patients whether
acute glucose metabolism, as indicated by fasting glycemia
and insulin resistance (HOMA index) was able to affect
short- and long-term mortality. In the overall population,
51 patients showed admission glucose values [140 mg/dl.
No significant difference was observed in admission and
peak glycemia, insulin and C-peptide values and in
HOMA-index between dead and survived patients. At
multivariate logistic backward stepwise analysis the fol-
lowing variables were independent predictors for in-ICCU
mortality (when adjusted for left ventricular ejection frac-
tion): Fibrinogen (1 mg/dl increase) [OR (95% CI) 0.991
(0.984–0.997); p = 0.004]; NT-pro BNP (100 UI increase)
[OR (95%CI) 1.005 (1.002–1.009); p = 0.004]; leukocyte
count (1,000/ll increase) [OR (95%CI) 1.252 (1.070–
1.464); p = 0.005]. eGFR was independently correlated
with long-term mortality (HR 0.96, 95%CI 0.94–0.98,
p \ 0.001). In consecutive patients with acute heart failure
without previously known diabetes, we documented, for
the first time, that fasting glucose and insulin values and
insulin resistance do not affect mortality at short- and long-
term. Inflammatory activation (as indicated by the leuko-
cyte count and the fibrinogen) and NT-pro BNP levels are
independent predictors for early death while the eGFR
affects the long-term mortality.
Keywords Acute heart failure  Acute glucose
dysmetabolims  Hyperglycemia  Insulin resistance 
Prognosis
Introduction
Glucose values and acute insulin resistance have been
investigated in various acute cardiac conditions [1–8].
The association between hyperglycemia and increased
mortality associated with acute coronary syndrome (ACS)
has been extensively studied and confirmed [1]. In patients
with ST elevation myocardial infarction (STEMI), hyper-
glycemia is common, and, though frequently untreated,
associated with an increased risk of death [1–5]. In these
patients, increased glucose values hold a prognostic role
when measured not only on admission [1], but also
throughout hospital stay [6–8]. The prognostic role of
hyperglycemia has also been reported in cardiogenic shock
complicating acute myocardial infarction [9–12]. Insulin
resistance, known to be part of the glyco-metabolic
response to stress, has been investigated in a few studies by
means of the Homeostatic Model Assessment (HoMA
index), in the early phase of acute myocardial infarction
[13] and in ACS patients [14]. In non-diabetic STEMI
patients submitted to PCI, we report that insulin resistance,
as assessed by HOMA-index, is quite common, and helps
in the early risk stratification, since it represents an inde-
pendent predictor for in-hospital mortality [15]. In patients
with ACS, insulin resistance quantified by the HOMA
index, seems to have a significant important prognostic
role, both in primary and secondary prevention [16].
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On the other hand, Kosiborod et al. [17] find no sig-
nificant association between admission glucose levels and
mortality in a large cohort of patients hospitalized with
heart failure, thus suggesting that the relationship between
hyperglycemia and adverse outcomes seen in acute myo-
cardial infarction cannot be automatically extended to
patients hospitalized with other cardiovascular conditions.
No data is so far available on the relation between
glucose values and insulin resistance and mortality, both at
short- and long-term, in patients with acute heart failure
syndromes (AHF) [18–21].
In the present investigation, we prospectively assessed
in 100 consecutive AHF patients whether acute glucose
metabolism, as indicated by fasting glycemia and insulin
resistance (HOMA index) was able to affect short and
long-term mortality.
Methods
We prospectively enrolled 100 consecutive patients with
AHFs [18–22] who were without previously known dia-
betes, admitted to our Intensive Cardiac Care Unit from 30
June 2008 to 30 June 2009.
Our series comprises AHF patients with ACS (submitted
to mechanical revascularization [23–27]), and those with
decompensated heart failure. All patients were rapidly
transferred to our ICCU either from the Emergency
Department (ED) or from the Catheterization Laboratory
after mechanical revascularization.
On ICCU admission, in a fasting blood sample, the
following parameters were measured: glucose (g/l), insulin
(UI/L), C-peptide (UI/L), troponin I (Tn I, ng/ml), uric acid
(mg/dl) [25, 28], NT-pro Brain Natriuretic Peptide (NT-
proBNP) (pg/ml) [24], leukocyte count (9103/ll), fibrino-
gen (mg/dl), erythrocyte sedimentation rate (ESR), lactate,
C-reactive protein (C-RP, mg/dl). Creatinine (mg/dl) was
also measured in order to calculate a glomerular filtration
rate (ml/min/1.73 m2) [29, 30]. Glucose values were
measured three times a day, and the peak glucose was
determined. In patients with STEMI and UA/NSTEMI, Tn
I levels were measured three times a day, and the peak TnI
level was determined.
Transthoracic 2-dimensional echocardiography was
performed on ICCU admission in order to measure the left
ventricular ejection fraction (LVEF).
Definition of insulin resistance
The criteria used for the definition of insulin resistance are
in accordance with the recently published guidelines pro-
posed by the European Group of the study of Insulin
Resistance (EGIR) [15]. HOMA was calculated according
to the following formula: {[fasting insulin (lU/ml)] 9
[fasting glucose (mmol/l)]}/22.5 [31]. Subjects whose
values exceeded the gender-specific 75th percentile (pct)
(i.e. 1.80 for women and 2.12 for men) were considered to
have insulin resistance (HOMA-IR) [32].
The study protocol was in accordance with the Decla-
ration of Helsinki and approved by the local Ethics Com-
mittee. Informed consent was obtained from all patients
before enrollment.
Mean follow-up (283 days (25th–75th pct: 39–406)
median follow-up 9.4 months (25th–75th pct: 1.3–13.6)
All surviving patients (83%) were contacted by clinical
interview or telephone as part of a prospective follow-up
program. The endpoint was all-cause death.
Statistical analysis
Analysis has been performed using SPSS 13.0 statistical
package (SPSS Inc., Chicago, IL, USA). Categorical data are
expressed as frequencies and percentages; continuous data
are reported as mean ± standard deviation (SD) or median
(25th–75th pct), according to a normal or non-normal data
distribution, assessed by means of Kolmogorov–Smirnov
one-sample test. Univariate analysis (chi-squared or Fisher’s
exact test for categorical data; Student’s t test or Mann–
Whitney U test for continuous data) was used to identify
candidate variables for multivariate analysis using a signif-
icant threshold. Backward stepwise logistic regression was
performed in order to identify predictors of in-ICCU mor-
tality. The Hosmer–Lemeshow test assessed the calibration
of the logistic model, and a c-statistic was used to test its
goodness-of fit. A Cox proportional hazards model was used
to compute adjusted hazard ratios and 95% confidence
intervals in order to assess the relation between each
predictor (chosen as above reported) and death at follow-up.
Survival analysis was performed by means of the Kaplan–
Meier survival curve; the log-rank test is reported. In
all cases, a two-tailed p value \0.05 was considered
significant.
Results
Our study population comprises patients with ACSs
(STEMI 21%, NSTEMI 26%) and decompensated chronic
heart failure (53%). In our series, the mean age was
73.9 ± 9.5 males and females were equally represented (49
and 51%, respectively). Hypertension was present in 77%,
while COPD was found in 18%. The length of stay was
76 h (46–158) and in-ICCU mortality was 17%.
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Ventilatory support was needed in 43% of all patients,
renal replacement therapy in 22%, while an intra-aortic
balloon pump was implemented in 19% (Table 1). As
depicted in Table 2, AHR patients with ACS showed
higher values of Tn I values (p \ 0.001) when compared to
those with decompensated HF. No other difference was
detectabale between the two groups. Table 3 shows the
comparison between patients who survived, and those who
did not. Survival patients exhibited an higher LVEF
(p = 0.026) and lower values of admission heart rate
(p \ 0.001). Mechanical ventilation and IABP were more
frequently used in patients who did not survive (p \ 0.001
and p = 0.003, respectively), while no significant differ-
ence was observed in regard to inotropic drugs between the
two subgroups.
Survival patients exhibited lower values of NT-pro
BNP, leukocyte, fibrinogen and lactate levels (p = 0.003,
p = 0.026, p = 0.030 and p = 0.047, respectively) in
comparison to dying patients, while no significant differ-
ence was observed in admission and peak glycemia, insulin
and C-peptide values and in HOMA-index between the two
subgroups. In the overall population, 51 patients showed
admission glucose values [140 mg/dl, with no difference
between dying and survival patients (dying patients
12/17—70.6%; survival patients 39/83—47%; chi-square
p = 0.076).
At multivariate logistic backward stepwise analysis the
following variables were independent predictors for in-
ICCU mortality (when adjusted for LVEF): Fibrinogen
(1 mg/dl increase) [OR (95% CI) 0.991 (0.984–0.997);
p = 0.004]; NT-pro BNP (100 UI increase) [OR (95% CI)
1.005 (1.002–1.009); p = 0.004]; leukocyte count (1,000/
ll increase) [OR (95% CI) 1.252 (1.070–1.464);
p = 0.005]; (Hosmer–Lemeshow v2: 11.742, 8 degrees of
freedom, p = 0.163); c-statistics goodness-of-fit: 84%
(p \ 0.001; sensitivity 73%, specificity 86%).
At long-term follow-up, neither admission glycemia nor
peak glycemia were significantly correlated with death
(univariable proportional hazards Cox regression analysis).
Admission glycemia: unadjusted HR 0.95, 95% CI
0.52–1.71, p = 0.861. Peak glycemia: unadjusted HR 0.93,
95% CI 0.58–1.50, p = 0.774.
At backward stepwise proportional hazards Cox
regression analysis, the eGFR was independently corre-
lated with long-term mortality (HR 0.96, 95% CI
0.94–0.98, p \ 0.001). Figure 1 shows a survival analysis
performed by means of the Kaplan–Meier survival curve.
Discussion
Acute heart failure syndromes remain a major cause of
morbidity and mortality, in part because of the lack of
definitive evidence for AHFS management and risk strati-
fication parameters [33]. As recently stated by Weintraub
et al. [21], there is a clinical need to identify clinical and
laboratory tools useful for risk stratification in the AHF
population, given its heterogeneity. Hyperglycemia and
acute insulin resistance in these patients may be addressed
for risk stratification as well as for treatment, but no data
are so far available on this topic.
In the present investigation performed in consecutive
patients with acute heart failure without previously known
diabetes, we document that fasting glucose and insulin
values and insulin resistance do not affect mortality at
short- and long-term. Inflammatory activation (as indicated
by leukocyte count and fibrinogen) and NT-pro BNP are
independent predictors for early death while thee GFR
affects the long-term mortality.
There is a paucity of data (mainly reported in retro-
spective papers) on the prognostic role of admission glu-
cose values in acute decompensated HF patients. In a
retrospective study, Shook et al. [34] examined admission
serum glucose in 77 Afro-American patients without a
history of diabetes, who were hospitalized with either
chronic, decompensated biventricular failure or acute left
heart failure, and find that hyperglycemias an infrequent
finding. In a large cohort of acute decompensated heart
failure patients, Novack et al. [35] retrospectically evalu-
ated the relationship between routine admission laboratory
tests results (including glucose levels), patient character-
istics and 30-day and 1-year mortality in patients admitted
for decompensated heart failure. Glucose values were the
only laboratory admission parameters that did not differ
between survivors and deceased patients, and there is no
association between glucose [200 mg/dL and 1-year
mortality in patients with without diabetes.
While hyperglycemia is well established as a prognostic
indicator and as a therapeutic target in ACS patients [1, 2],
Table 1 Devices and inotropic agents
Frequency (%)








cPAP continuous positive pressure ventilation, CVVHDF continuous
veno-venous hemo-dia ultrafiltration, IABP intra aortic balloon pump,




in AHF patients according to our results, glucose values
and insulin resistance lack any prognostic significance at
short- and long-term. Our findings are in agreement with
those by Kosiborod et al. [17], who find no significant
association between admission glucose levels and mortality
in a large cohort of patients hospitalized with heart failure.
Similarly, Falciglia et al. [36] report, in a large and
heterogeneous cohort of critically ill patients, that hyper-
glycemia-related mortality is disproportionately greater in
some medical conditions than others, suggesting differ-
ences in the interaction between specific medical condi-
tions and injury from hyperglycemia.
In keeping with these previous findings [17, 36], our
data strongly suggest that hyperglycemia related risk may
Table 2 Comparison between AHF patients in acute coronary syndromes and those in decompensated heart failure
Mean ± standard deviation or median (IR) or frequency (%) p value
AHF in ACS (n = 47) AHF in decompensated (n = 53)
Age (mean ± SD, years) 75.0 ± 9.5 73.0 ± 9.5 0.307t
Gender [males/females, frequency (%)] 24/23 (51.1/48.9%) 25/28 (47.2/52.8%) 0.697C
Comorbidities [frequency (%)]
Hypertension, frequency (%) 36 (76.6%) 41 (77.4%) 0.928t
COPD, frequency (%) 9 (19.1%) 9 (17.0%) 0.778C
LVEF (%) 32.0 ± 9.6 31.1 ± 9.4 0.628t
Admission heart rate (mean ± SD, beats/min) 89.5 ± 23.7 86.8 ± 20.9 0.554t
Admission systolic blood pressure (mean ± SD, mmHg) 124 ± 25 116 ± 28 0.146t
LOS [median (IR), h] 96 (32–148) 72 (48–144) 0.549U
Devices
Mechanical ventilation 8 (17.0%) 16 (30.2%) 0.124C
cPAP 7 (14.9%) 12 (22.6%) 0.324C
CVVHDF 7 (14.9%) 15 (28.3%) 0.106C
IABP 14 (29.8%) 5 (9.4%) 0.010C
Inotropic agents
Norepinephrine 4 (8.5%) 6 (11.3%) 0.746F
Dobutamine 3 (6.4%) 9 (17.0%) 0.104C
Dopamine 15 (31.9%) 18 (34.0%) 0.828C
Laboratory data
Admission glucose (g/l) 1.67 ± 0.70 1.56 ± 0.72 0.418t
Peak glycemia (g/l) 2.08 ± 0.72 1.91 ± 0.87 0.302t
Insulinemia (UI/l) 13.5 (5.9–21.5) 10.8 (5.3–31.0) 0.856U
HOMA-index 0.75 (0.30–1.54) 0.63 (32–1.83) 0.643U
C-peptide (UI/l) 1.02 (0.60–1.61) 0.94 (0.63–1.66) 0.762U
NT-pro BNP (pg/ml) 10,582 (3,674–20,058) 7,754 (3,490–16,958) 0.259U
Tn I (ng/ml) 32.3 (5.8–111.4) 0.9 (0.2–3.4) \0.001U
C-reactive protein positivity 41 (87.2%) 38 (71.7%) 0.045C
Leukocytes (91,000/ll) 10.7 ± 4.2 10.9 ± 4.2 0.809t
Fibrinogen (mg/dl) 516 ± 126 488 ± 124 0.288t
Uric acid (mg/dl) 7.0 ± 2.6 6.5 ± 2.5 0.363t
Lactate (mmol/l) 1.1 (0.8–2.0) 1.1 (0.9–3.4) 0.946U
eGFR (ml/min/1.73 m2) 64.2 ± 27.1 54.8 ± 36.3 0.147t
ICCU deaths 6 (12.8%) 11 (20.8%) 0.288C
Follow-up deaths 10 (24.4%) 16 (38.1%) 0.178C
Follow-up length [median (IR), days] 371 (112–421) 255 (24–402) 0.199U
COPD chronic obstructive pulmonary disease, LVEF left ventricular ejection fraction, LOS length of stay, cPAP continuous positive pressure
ventilation, CVVHDF continuous veno-venous hemo-dia ultrafiltration, IABP intra-aortic balloon pump, HOMA homeostatic model assessment,
NT-pro-BNP N terminal brain natriuretic peptide, eGFR estimated glomerular filtration rate, SD standard deviation, interquartile range, ICCU
intensive cardiac care unit, t Student’s t test, C Chi-square test, U Mann–Whitney U test, F Fisher’s exact test
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vary with the underlying conditions in acute cardiac
patients, being strong and well established in ACS patients
and weak in AHF syndromes.
Finally, we observe that renal function (as indicated by
eGFR) is an independent predictor of long-term mortality.
Our finding is in keeping with previous investigations in
which the admission and discharge eGFR are both strong
univariate predictors of mortality [37, 38].
A possible limitation of the present study is that, since it
is a single center experience, it comprises a small number
of patients. However, our population comprises consecu-
tive AHF patients, acutely admitted to our ICCU shortly
after hospital arrival, thus mirroring the real world
scenario.
In conclusion, in consecutive patients with acute heart
failure without previously known diabetes, we document
that fasting glucose and insulin values and insulin resis-
tance do not affect mortality at short- and long-term.
Inflammatory activation (as indicated by the leukocyte
count and the fibrinogen) and NT-pro BNP levels are
Table 3 Comparison between survivors and non-survivors
Mean ± standard deviation or median (IR) or frequency (%) p value
Survivors (n = 83) Non survivors (n = 17)
Age (mean ± SD, years) 73.6 ± 9.0 75.7 ± 12.0 0.492
Gender [males/females, frequency (%)] 41/42 (49.4/50.6%) 8/9 (47.1/52.9%) 0.860
Comorbidities [frequency (%)]
Hypertension, frequency (%) 64 (77.1%) 13 (76.5%) 0.955
COPD, frequency (%) 14 (16.9%) 4 (23.5%) 0.501*
LVEF, frequency (%) 32.5 ± 8.8 26.9 ± 11.4 0.026
Admission heart rate (mean ± SD, beats/min) 88.0 ± 20.9 88.5 ± 28.9 0.936
Admission systolic blood pressure (mean ± SD, mmHg) 124 ± 25 94 ± 23 \0.001
LOS [median (IR), h] 87 (48–144) 48 (3.5–267) 0.318
Devices
Mechanical ventilation 10 (12.0%) 14 (82.4%) \0.001
cPAP 14 (16.9%) 5 (29.4%) 0.306
CVVHDF 15 (18.1%) 7 (41.2%) 0.053
IABP 11 (13.3%) 8 (47.1%) 0.003
Inotropic agents
Norepinephrine 6 (7.2%) 4 (23.5%) 0.064
Dobutamine 9 (10.8%) 3 (17.6%) 0.424
Dopamine 24 (28.9%) 9 (52.9%) 0.087
Laboratory data
Admission glucose 1.58 ± 0.72 1.75 ± 0.70 0.401
Peak glycemia 1.96 ± 0.82 2.15 ± 0.70 0.397
Insulinemia 11.9 (5.9–22.3) 7.1 (3.6–12.8) 0.130
HOMA-index 0.72 (0.32–1.70) 0.31 (0.23–1.26) 0.209
C-peptide 0.97 (1.64–1.38) 1.62 (0.48–2.50) 0.804
NT-pro BNP 7,329 (3,330–15,844) 24,131 (10,803–33,640) 0.003
Tn I 2.49 (0.34–34.29) 45.60 (5.24–232.93) 0.804
C-reactive protein positivity 65 (78.3%) 13 (100%) 0.0487*
Leukocytes (91,000/ll) 10.34 ± 3.95 12.96 ± 5.02 0.026
Fibrinogen 513 ± 120 437 ± 134 0.030
Uric acid 6.8 ± 2.4 6.6 ± 3.7 0.898
Lactate 0.9 (0.8–1.6) 3.3 (1.8–12.8) 0.047
eGFR (ml/min/1.73 m2) 61.6 ± 30.4 48.0 ± 42.0 0.137
COPD chronic obstructive pulmonary disease, LVEF left ventricular ejection fraction, LOS length of stay, cPAP continuous positive pressure
ventilation, CVVHDF continuous veno-venous hemo-dia ultrafiltration, IABP intra-aortic balloon pump, HOMA homeostatic model assessment,
NT-pro-BNP N terminal brain natriuretic peptide, eGFR estimated glomerular filtration rate, SD standard deviation, interquartile range, ICCU
intensive cardiac care unit
* Fisher’s exact test
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independent predictors for early death while the eGFR
affects long-term mortality.
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